



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

### Complete if Known

Application Number	10/534,242
Filing Date	May 9, 2005
First Named Inventor	Richard Joseph Fagan
Art Unit	1645 1644
Examiner Name	Sharon Wen

Sheet

1

of

3

Attorney Docket Number

C&R-101

### U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
U1	US-				
U2	US-				
U3	US-				
U4	US-				
U5	US-				
U6	US-				
U7	US-				
U8	US-				
U9	US-				

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>4</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
/S.W./	F1	WO 02/079398 A2 (on CD)	10-10-2002	Curagen Corp.	All	
	F					
	F					
	F					
	F					
	F					
	F					

Examiner Signature

/Sharon Wen/

Date Considered

08/27/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-788-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  
**INFORMATION DISCLOSURE  
 STATEMENT BY APPLICANT**  
 (use as many sheets as necessary)

Sheet

2

of

3

**Complete if Known**

Application Number	10/534,242
Filing Date	May 9, 2005
First Named Inventor	Richard Joseph Fagan
Group Art Unit	1646 1644
Examiner Name	Sharon Wen

Attorney Docket Number C&amp;R-101

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/S.W./	R1	NIELSEN, K. et al. "Amino acid sequence of hen ovomacroglobulin (ovostatin) deduced from cloned cDNA" <i>J. DNA Sequencing and Mapping</i> , 1994, 5(2):111-119.	
	R2	NAGASE, H. et al. "Ovostatin a novel proteinase inhibitor from chicken egg white 1. Purification physicochemical properties and tissue distribution of ovostatin" <i>J. Biol. Chem.</i> , 1983, 258(12):7481-7489.	
	R3	QAZI, U. et al. "On the structural changes of native human alpha2-macroglobulin upon proteinase entrapment: Three-dimensional structure of the half-transformed molecule" <i>J. Biol. Chem.</i> , 1998, 273(15):8987-8993.	
	R4	RAMOS, A. M. et al. "Trypanosoma cruzi: Cruzipain and Membrane-Bound Cysteine Proteinase Isoform(s) Interacts with Human $\alpha_2$ -macroglobulin and Pregnancy Zone Protein", <i>Experimental Parasitology</i> , 2002, pp. 121-130, Vol. 100.	
	R5	LIN, M. et al. "Cell Surface Antigen CD109 is a Novel Member of the $\alpha_2$ Macroglobulin/C3, C4, C5 Family of Thioester-containing Proteins", <i>Blood</i> , March 1, 2002, pp. 1683-1691, Vol. 99, No. 5.	
	R6	SHERMAN, S. K. et al. "Role of the Complement System in Ischaemic Heart Disease", <i>BioDrugs</i> , 2001, pp. 595-607, Vol. 15, No. 9.	
	R7	ASAMI, T. et al. "Study on Proteinase-Inhibiting Capacity of Plasma $\alpha_2$ -Macroglobulin in Idiopathic Nephrotic Syndrome", <i>Nephron</i> , 1996, pp. 512-517, Vol. 72.	
	R8	PETERSON, C. M. " $\alpha_2$ -Macroglobulin and Pregnancy Zone Protein", <i>Danish Medical Bulletin</i> , September 1993, pp. 409-446, Vol. 40, No. 4.	
	R9	HONG, T. et al. "A Study on the Serum Pregnancy Zone Protein Levels in Pregnant Women and Patients with Gynecological Tumors", <i>Chinese Medical Journal</i> , 1994, pp. 910-914, Vol. 107, No. 12.	
	R10	ZAPPIA, M. et al. "Genetic Association of $\alpha_2$ -Macroglobulin Polymorphisms with AD in Southern Italy", <i>Neurology</i> , September 2002, pp. 756-758, Vol. 59.	
	R11	GENNARO, R. et al. "C5a Fragment of Bovine Complement", <i>Eur. J. Biochem.</i> , 1986, pp. 77-86, Vol. 155.	
	R12	FRITZINGER, D. C. et al. "Primary Structure of Cobra Complement Component C3", <i>The Journal of Immunology</i> , December 1, 1992, pp. 3554-3562, Vol. 149, No. 11.	
▼	R13	SANDOVAL, A. et al. "Distal Recognition Site for Classical Pathway Convertase Located in the C345C/Netrin Module of Complement Component C5", <i>The Journal of Immunology</i> , 2000, pp. 1066-1073, Vol. 165.	

Examiner Signature	/Sharon Wen/	Date Considered	08/27/2007
--------------------	--------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  
**INFORMATION DISCLOSURE  
 STATEMENT BY APPLICANT**  
 (use as many sheets as necessary)

Sheet

3

of

3

**Complete if Known**

Application Number	10/534,242
Filing Date	May 9, 2005
First Named Inventor	Richard Joseph Fagan
Group Art Unit	T645 1644
Examiner Name	Sharon Wen

Sheet

3

of

3

Attorney Docket Number

C&amp;R-101

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/S.W./	R14	NIELSEN, K. L. et al. "Identification of Residues in $\alpha$ -Macroglobulins Important for Binding to the $\alpha_2$ -Macroglobulin Receptor/Low Density Lipoprotein Receptor-related Protein", <i>The Journal of Biological Chemistry</i> , May 31, 1996, pp. 12909-12912, Vol. 271, No. 22.	
	R15	BHATIA, M. et al. "Complement Factor C5a Exerts an Anti-Inflammatory Effect in Acute Pancreatitis and Associated Lung Injury", <i>Am. J. Physiol. Gastrointest. Liver Physiol.</i> , 2001, pp. G974-G978, Vol. 280.	
	R16	SOTTRUP-JENSEN, L. " $\alpha$ -Macroglobulins: Structure, Shape, and Mechanism of Proteinase Complex Formation", <i>The Journal of Biological Chemistry</i> , July 15, 1989, pp. 11539-11542, Vol. 264, No. 20.	
	R17	NICOLETTI, G. et al. "No Evidence of Association Between the Alpha-2 Macroglobulin Gene and Parkinson's Disease in a Case-Control Sample", <i>Neuroscience Letters</i> , 2002, pp. 65-67, Vol. 328.	
	R18	O'BARR, S. et al. "The C5a Complement Activation Peptide Increase IL-1 $\beta$ and IL-6 Release from Amyloid- $\beta$ Primed Human Monocytes: Implications for Alzheimer's Disease", <i>Journal of Neuroimmunology</i> , 2000, pp. 87-94, Vol. 109.	
	R19	CISLO, M. et al. "Allelic Distribution of Complement Components BF, C4A, C4B, and C3 in <i>Psoriasis vulgaris</i> ", <i>Immunology Letters</i> , 2002, pp. 145-149, Vol. 80.	
	R20	TANG, G. et al. "Alpha-2 Macroglobulin I1000V Polymorphism in Chinese Sporadic Alzheimer's Disease and Parkinson's Disease", <i>Neuroscience Letters</i> , 2002, pp. 195-197, Vol. 328.	
	R21	KÖHL, J. "Anaphylatoxins and Infectious and Non-Infectious Inflammatory Diseases", <i>Molecular Immunology</i> , 2001, pp. 175-187, Vol. 38.	
	R22	GHEBREMEDHIN, E. et al. "Genetic Association of Argyrophilic Granule Disease with Polymorphisms in Alpha-2 Macroglobulin and Low-Density Lipoprotein Receptor-Related Protein Genes", <i>Neuropathology and Applied Neurobiology</i> , 2002, pp. 308-313, Vol. 28.	
	R23	EGGERTSEN, G. et al. "Sequence of Rat $\alpha_1$ -Macroglobulin, a Broad-range Proteinase Inhibitor from the $\alpha$ -Macroglobulin-complement Family", <i>Mol. Biol. Med.</i> , 1991, pp. 287-302, Vol. 8.	
	R24	OGATA, R. T. et al. "Sequence of the Gene for Murine Complement Component C4", <i>The Journal of Biological Chemistry</i> , October 5, 1989, pp. 16565-16572, Vol. 264, No. 28.	
▼	R25	NAGASE, H. et al. "Evidence for a Thiol Ester in Duck Ovostatin (Ovomacroglobulin)", <i>The Journal of Biological Chemistry</i> , January 25, 1986, pp. 1421-1426, Vol. 261, No. 3.	
	R		

Examiner Signature	/Sharon Wen/	Date Considered	08/27/2007
--------------------	--------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.